EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Researchers performed a retrospective analysis to evaluate the use of Endothelial Activation and Stress Index (EASIX) and modified EASIX (m-EASIX) scores to predict cytokine release syndrome (CRS) and immune-effector cell associated neurotoxicity syndrome (ICANS) in pediatric and adolescent and young adult (AYA) patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were treated with CD19 CAR T-cell therapy. Although EASIX and m-EASIX have been retrospectively proven to predict CRS and ICANS in adult patients, they had previously not been evaluated among pediatric and AYA patients. The researchers found that both EASIX and m-EASIX scores were strong predictors of CRS and ICANS in this pediatric and AYA group, validating the potential use of these scores in this patient population.